• 1
    Eytan GD, Kuchel PW. Mechanism of action of p-glycoprotein in relation to passive membrane permeation. Int Rev Cytol 1999; 190:175250.
  • 2
    Ganapathi R, Hoeltge G, Casey G, Grabowski D, Neelon R, Ford J. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies. Cancer Genet Cytogenet 1996; 86:1169.
  • 3
    Tsimberidou AM, Paterakis G, Androutsos G et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukaemia. Leuk Res 2002; 26:14354.
  • 4
    Wigler PW, Patterson FK. Inhibition of the multidrug resistance efflux pump. Biochim Biophys Acta 1993; 1154:117381.
  • 5
    Hoffman MM, Wei LY, Roepe PD. Are altered pHi and membrane potential in huMDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance? J Gen Physiol 1996; 108:295313.
  • 6
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:196772.
  • 7
    Wigler PW, Patterson FK. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta 1994; 1189:16.
  • 8
    Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumour cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83:77859.
  • 9
    Capone PM, Papsidero LD, Croghan GA, Chu TM. Experimental tumoricidal effects of monoclonal antibody against solid breast tumours. Proc Natl Acad Sci USA 1983; 80:732832.
  • 10
    Chapman PB, Lomberg M, Houghton AM. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumour targeting, and antitumour activity. Cancer Res 1990; 50:15039.
  • 11
    Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:105866.
  • 12
    Kojima A, Iwata K, Seya T et al. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151:151927.
  • 13
    Medof ME, Kinoshita T, Nussenzweig V Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160:155878.
  • 14
    Meri S, Morgan BP, Davies A et al. Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71:19.
  • 15
    Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumours. Mol Immunol 2003; 40:10923.
  • 16
    Jurianz K, Ziegler S, Garcia-Schuler H et al. Complement resistance of tumour cells: basal and induced mechanisms. Mol Immunol 1999; 36:92939.
  • 17
    Gorter A, Meri S. Immune evasion of tumour cells using membrane-bound complement regulatory proteins. Immunol Today 1999; 20:57682.
  • 18
    Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb mediated cancer immunotherapy. Trends Immunol 2004; 25:15864.
  • 19
    Bomstein Y, Fishelson Z. Enhanced sensitivity of P-glycoprotein-positive multidrug resistant tumour cells to complement-mediated lysis. Eur J Immunol 1997; 27:220411.
  • 20
    Weisburg JH, Curcio M, Caron PC et al. The multidrug resistance phenotype confers immunological resistance. J Exp Med 1996; 183:2699704.
  • 21
    Masanek U, Stammler G, Volm M. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 1997; 8:18998.
  • 22
    Fruehauf S, Breems DA, Knaan-Shanzer S et al. Frequent analysis of multidrug resistance-1 gene transfer into human primitive hematopietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum Gene Ther 1996; 7:121931.
  • 23
    Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 1999; 42:20918.
  • 24
    Hildinger M, Schilz A, Eckert HG et al. Bicistronic retroviral vectors for combining myeloprotection with cell-surface marking. Gene Ther 1999; 6:122230.
  • 25
    Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 2001; 93:84854.
  • 26
    Gambacorti-Passerini C, Rivoltini L, Supino R et al. Susceptibility of chemoresistant murine and human tumour cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988; 48:23726.
  • 27
    Roepe PD, Wei LY, Cruz J, Carlson D. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993; 32:1104256.
  • 28
    Rothnie A, Theron D, Soceneantu L et al. The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur Biophys J 2001; 30:43042.
  • 29
    Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J Biol Chem 1999; 274:1087788.
  • 30
    Johnstone RW, Tainton KM, Ruefli AA et al. P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. J Biol Chem 2001; 276:1666773.
  • 31
    Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003; 131:25463.
  • 32
    Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70:1425.
  • 33
    Surowiak P, Materna V, Maciejczyk A et al. CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer Res 2006; 26:49438.
  • 34
    Junnikkala S, Hakulinen J, Jarva H et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002; 87:111927.
  • 35
    Bjorge L, Hakulinen J, Vintermyr OK, Jarva TS, Iversen OE, Meri S. Ascitic complement system in ovarian cancer. Br J Cancer 2005; 92:895905.
  • 36
    Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000; 164:607581.
  • 37
    Blok VT, Daha MR, Tijsma O et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumour-associated antigen G250 enhances C3 deposition and tumour cell lysis by complement. J Immunol 1998; 160:343743.
  • 38
    Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82:48393.
  • 39
    Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ. Expression of CD46, CD55, and CD59 on renal tumour cell lines and their role in preventing complement-mediated tumour cell lysis. Lab Invest 1996; 74:103949.
  • 40
    Kuraya M, Yefenof E, Klein G, Klein E. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur J Immunol 1992; 22:18716.
  • 41
    Maio M, Brasoveanu LI, Coral S et al. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies. Int J Oncol 1998; 13:30518.
  • 42
    Bjørge L, Matre R. Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Scand J Immunol 1995; 42:5126.
  • 43
    Sedlak J, McGown A, Hrubisko M, Hunakova L, Chorvath B. Drug-resistance associated alterations of cell surface antigen expression in a human anthracycline-resistant ovarian carcinoma cell line. Neoplasma 1994; 41:25962.
  • 44
    Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 2001; 85:117584.
  • 45
    Zaman GJ, Flens MJ, Van Leusden MR et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994; 91:88226.
  • 46
    Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95:1566570.